Loading
A phase 2 trial of Tigilanol Tiglate in sarcomas, run by QBiotics Group Limited, now recruiting.
A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma is a phase 2 interventional study registered as NCT05755113 by QBiotics Group Limited, with 40 participants planned, started 2023-04-13 and due to reach its primary completion in 2027-01. Interventions recorded: Tigilanol Tiglate.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares QBiotics and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/